NASDAQ:ARDS - Aridis Pharmaceuticals Stock Price, Forecast & News

Aridis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARDS."

Aridis Pharmaceuticals Inc (NASDAQ:ARDS) announced its earnings results on Wednesday, November, 13th. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.33) by $0.54. View Aridis Pharmaceuticals' Earnings History.

Aridis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Aridis Pharmaceuticals.

4 Wall Street analysts have issued 1-year price targets for Aridis Pharmaceuticals' shares. Their forecasts range from $7.00 to $25.00. On average, they expect Aridis Pharmaceuticals' stock price to reach $17.25 in the next twelve months. This suggests a possible upside of 132.9% from the stock's current price. View Analyst Price Targets for Aridis Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aridis Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aridis Pharmaceuticals.

News headlines about ARDS stock have been trending somewhat positive on Monday, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Aridis Pharmaceuticals earned a news sentiment score of 1.7 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Aridis Pharmaceuticals.

Aridis Pharmaceuticals saw a increase in short interest in the month of December. As of December 13th, there was short interest totalling 32,200 shares, an increase of 45.7% from the November 28th total of 22,100 shares. Based on an average daily volume of 6,200 shares, the days-to-cover ratio is currently 5.2 days. Currently, 0.6% of the company's stock are short sold. View Aridis Pharmaceuticals' Current Options Chain.

Some companies that are related to Aridis Pharmaceuticals include Kamada (KMDA), MEI Pharma (MEIP), BIOFRONTERA AG/ADR (BFRA), Concert Pharmaceuticals (CNCE), Advanz Pharma (CXRXF), Syndax Pharmaceuticals (SNDX), Hookipa Pharma (HOOK), Seres Therapeutics (MCRB), Affimed (AFMD), Aeglea Bio Therapeutics (AGLE), Kala Pharmaceuticals (KALA), Ocular Therapeutix (OCUL), Cerecor (CERC), LifeVantage (LFVN) and Theratechnologies (THTX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Aridis Pharmaceuticals investors own include Juno Therapeutics (JUNO), Anavex Life Sciences (AVXL), Nektar Therapeutics (NKTR), Progenics Pharmaceuticals (PGNX), Tandem Diabetes Care (TNDM), Abeona Therapeutics (ABEO), Aclaris Therapeutics (ACRS), Fate Therapeutics (FATE), Genocea Biosciences (GNCA) and Krystal Biotech (KRYS).

(ARDS) raised $28 million in an IPO on Tuesday, August 14th 2018. The company issued 2,000,000 shares at a price of $13.00-$15.00 per share. Cantor served as the underwriter for the IPO and Maxim Group and Northland Capital Markets were co-managers.

Shares of ARDS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ARDS stock can currently be purchased for approximately $7.41.

Aridis Pharmaceuticals has a market capitalization of $65.98 million and generates $2.76 million in revenue each year. The company earns $-22,100,000.00 in net income (profit) each year or ($7.01) on an earnings per share basis. Aridis Pharmaceuticals employs 23 workers across the globe.View Additional Information About Aridis Pharmaceuticals.

The official website for Aridis Pharmaceuticals is http://www.aridispharma.com/.

Aridis Pharmaceuticals' mailing address is 5941 Optical Ct., San Jose CA, 95138. The company can be reached via phone at 408-385-1742 or via email at [email protected]